Prevention, Combination Therapy, and Comparative Effectiveness Research in Alzheimer's Disease
Funds human studies on drug-based precision prevention, combination therapies, and comparative effectiveness to reduce Alzheimer's and dementia risk, prioritizing interventions targeting specific biological mechanisms.
Funder: Alzheimer's Drug Discovery Foundation
Due Dates: September 14, 2026: Letter of Intent deadline (must be received by 5:00 pm ET)
Funding Amounts: Up to $5,000,000 per award for clinical trials; multi-year funding; direct costs only; milestone-based payments.
Summary: Funds human studies on precision prevention, combination therapies, and comparative effectiveness to reduce Alzheimer's and dementia risk, prioritizing drug-based interventions.
Key Information: Lifestyle-only and anti-amyloid approaches are not eligible; funding is structured as mission-related investment, not a traditional grant.
Description
This opportunity supports human studies investigating precision prevention, combination therapies, and comparative effectiveness research aimed at reducing the risk of Alzheimer's disease and other dementias. Priority is given to interventions targeting specific risk factors or biological mechanisms (e.g., metabolic, vascular, inflammatory, neuroprotective pathways) using novel, repurposed, or repositioned drugs, supplements, or devices. Projects may include randomized controlled trials, epidemiological studies, or long-term follow-up of prevention trials. The program encourages studies with intellectual property or commercial potential and combination therapies, as well as comparative effectiveness research among clinically equivalent drugs. Lifestyle-only interventions and anti-amyloid approaches are ineligible.
